Immuneering Could Partner Atebimetinib Or Go It Alone After Phase IIa Success

CEO Ben Zeskind said all options are on the table after atebimetinib showed impressive results in pancreatic cancer.

Pancreatic cancer
• Source: Shutterstock

Immuneering Corporation is planning a global pivotal trial in 2026 for atebimetinib in first-line pancreatic cancer after posting successful results of a Phase IIa study of the drug. Immuneering is aiming to position atebimetinib for accelerated approval by the US Food and Drug Administration, but is still hashing out how it will fund and design the trial. Partnering or self-financing options are both on the table.

Key Takeaways
  • Immuneering announced positive results for its trial of atebimetinib in first-line pancreatic cancer and plans to launch a pivotal trial in 2026.

The Cambridge, MA-based biotech announced positive results on June 17 of the drug, a MEK inhibitor, combined with gemcitabine/nab-paclitaxel on...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Clinical Trials

Novartis Secures Approval For First Malaria Therapy for Babies

 
• By 

Coartem Baby to be rolled out in eight African countries in the autumn.

Could Apogee Rival Regeneron/Sanofi, Lilly After Phase II Eczema Data Win?

 
• By 

Apogee Therapeutics reports data from Phase II APEX trial of its long-acting antibody against atopic dermatitis, showing similar efficacy to Regeneron/Sanofi’s Dupixent and Eli Lilly’s Ebglyss.

Cogent Peaks With Bezaclastinib SUMMIT Results

 

The biotech announced positive topline results from the Phase II SUMMIT study in non-advanced systemic mastocytosis, with data for advanced SM and GIST expected later this year.

France’s AB Science Plots Pivotal Masitinib Trial In Prostate Cancer

 
• By 

Still holding out hope after multiple rejections for the tyrosine kinase inhibitor.

More from Therapy Areas